ImpaQ Ecosystem•Clarivate, Scopus & CORE Data
Clarivate WoS 2024 / 2025 Data
IMPAQ
WoS SCIE Q2Scopus Q2SCImago #9,777Hybrid

Journal of Pharmaceutical and Biomedical Analysis

Acronym:jpba
•
Abbreviation (ISO):J. PHARM. BIOMED. ANAL
•
Identifier (ISSN):0731-7085(Print)/1873-264X(Online)
•
Publisher:Elsevier
Clarivate IF (2026)
3.4↑ +0.3
Journal Impact Factor
IF Trend↓
WoS Quartile
Q2
WoS SCIEJCR Quartile
Clarivate WoS JCR
WoS Categories↓
JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Journal of Pharmaceutical and Biomedical Analysis

WoS Q2
13462.8320182.9820193.2120203.9420213.5720223.420233.120243.120253.42026
Annual Impact Factor Metric
Current (2026):3.4
Scopus SJR & RankScopus Q2
0.604
#9,777

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025
H-Index (2025)
160

160 papers with at least that number of citations each

WoS: SCIE / JCRQ2
Self-Citation Rate6.5%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessHybrid
746articles/year
17.93% Gold OA•96.55% Original Research

Aims & Scope

This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focusing on drug purity and stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance in the pharmaceutical industry are also welcome. Studies from areas of well established and poorly selective methods, such as UV-VIS spectrophotometry (including derivative and multi-wavelength measurements), basic electroanalytical (potentiometric, polarographic and voltammetric) methods, fluorimetry, flow-injection analysis, etc. are accepted for publication in exceptional cases only, if a unique and substantial advantage over presently known systems is demonstrated. The same applies to the assay of simple drug formulations by any kind of methods and the determination of drugs in biological samples based merely on spiked samples. Drug purity/stability studies should contain information on the structure elucidation of the impurities/degradants.

Topics Covered (Recognized by AI)
ChemistryChromatographyBiologyOrganic ChemistryPhysicsMedicineBiochemistryQuantum MechanicsInternal MedicineGeneticsMathematicsPhysical ChemistryStatisticsPharmacologyEndocrinologyMaterials ScienceBioinformaticsEngineering
Primary Research Areas

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
JCRSCIE2026

CHEMISTRY, ANALYTICAL

Q2
Rank48/110
IndexSCIE
JCRSCIE2026

PHARMACOLOGY & PHARMACY

Q2
Rank143/356
IndexSCIE
JCISCIE2026

CHEMISTRY, ANALYTICAL

Q2
Rank33/110
IndexSCIE
JCISCIE2026

PHARMACOLOGY & PHARMACY

Q2
Rank111/356
IndexSCIE

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
2026Latest
IF3.4
Articles / Year331
Total Citations146
2025
IF3.1
Articles / Year576
Total Citations1,572
2024
IF3.1
Articles / Year590
Total Citations3,791
2023
IF3.4
Articles / Year619
Total Citations6,085
2022
IF3.571
Articles / Year557
Total Citations7,722

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #9,777Scopus Q2SCImago Profile
Scopus Coverage:1983-2026
Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyChemistryPharmacology, Toxicology and Pharmaceutics
Scopus Citation Rank (SJR)Q2
0.604

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q2
Citations / Doc (2 years)
3.66

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,045 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations6,442
3-Year Documents1,706
Citable Documents1,697

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)1

Citations in government and international policy documents

Female Author Rate46.9%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Analytical ChemistryQ2
Drug DiscoveryQ2
Pharmaceutical ScienceQ2
SpectroscopyQ2
Clinical BiochemistryQ3
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 6.5%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
3区 (Zone 3)Medicine
Minor Category (Specific Field):
3区CHEMISTRY, ANALYTICAL
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Journal of Pharmaceutical and Biomedical Analysis (acronym: jpba, abbr: J. PHARM. BIOMED. ANAL, ISSN: 0731-7085) is a peer-reviewed international scholarly journal in the field of Medicine, published by Elsevier in Netherlands since 1983. The periodical holds a Journal Impact Factor (JIF) of 3.40, ranking in quartile Q2 of Web of Science (SCIE), a Scopus SJR indicator of 0.604 (Q2), an H-index of 160.

The journal enforces rigorous peer evaluation with an average review speed of 6.5周, a publication frequency of Semimonthly, an annual output of approximately 746 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,045 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Open Access Model
Hybrid
Publisher
Elsevier
Publication Language
English
Frequency
Semimonthly
Founding Year
1983
Indexing & Databases
SCIEScopusPubMed
Editorial Address
ELSEVIER SCIENCE BV, PO BOX 211, AMSTERDAM, NETHERLANDS, 1000 AE

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 2577a86b-2c89-488a-95ff-85c86a86d025
Database Updated: 2026-10-16